This is a summary of the European public assessment report (EPAR) for Corlentor. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Corlentor.
Corlentor : EPAR - Summary for the public (PDF/89.68 KB)
First published: 18/07/2006
Last updated: 11/02/2015
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Les Laboratoires Servier
|Date of issue of marketing authorisation valid throughout the European Union||
10/01/2018 Corlentor - EMEA/H/C/000598 - WS/1180
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Treatment of coronary-artery disease
Symptomatic treatment of chronic stable angina pectoris in coronary-artery-disease patients with normal sinus rhythm. Ivabradine is indicated:
- in patients unable to tolerate or with a contraindication to the use of beta-blockers;
- or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose and whose heart rate is > 60 beats per minute (bpm).
Treatment of chronic heart failure
Ivabradine is indicated in chronic heart failure New York Heart Association II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 November 201421/11/2014
European Medicines Agency recommends measures to reduce risk of heart problems with Corlentor/Procoralan (ivabradine)21/11/2014
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 November 201322/11/2013
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 201116/12/2011